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Objectives: The purpose of this study was to assess the anti-inflammatory, analgesic and osteogenic early effects 
of melatonin on post-extraction sockets ofpatients requiring third molars extraction. 
Study Design: A randomized, triple-blind clinical trial was made using a split-mouth design. Both lower third 
molars of 10 patients were extracted and 3 mg of local melatonin or placebo were applied. Concentrations of 
interleukin-6 and nitrotyrosine were determined on samples of the clot from the socket by independent ELISA 
tests. Radiographic bone density was evaluated by measuring Hounsfield Units in panoramic and cross sections 
obtained by digital scanner. Statistycal analysis by Kolmogorov-Smirnov test was performed for ELISA data. 
Bone density was analyzed by Shapiro-Wilk test. Subsequently t test was applied. P<0.05 was considered to be 
significant.
Results: The concentration of interleukin-6 increased with the application of melatonin without statistically sig-
nificance (361.32 ± 235.22 pg/ml vs 262.58 ± 233.92 pg/ml). Nitrotyrosine concentrations showed values below to 
the detectability pattern (<0.001 nM) in Optic Density curve. Bone density in panoramic sections at socket after 
melatonin application showed no significant difference (561.98 ± 105.92 HU vs 598.82 ± 209.03 HU). In cross sec-
tions, bone density in the alveolar region showed no significant difference(377.42 ± 125.67 HU vs 347.56 ± 97.02 
HU).
Conclusions: Within the limitations of this pilot study, no differences with the application of melatonin were found 
in terms of the concentration of interleukin-6 and bone density in post-extraction socket of retained mandibular 
third molars.
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Introduction
Third molar surgery is the most common intervention in 
oral surgery and is commonly recognized by patients as 
an unpleasant experience during the postoperative pe-
riod (1,2). Moreover, tooth loss is a functional, aesthetic 
and psychological problem in patients who request for a 
non-removable treatment for tooth replacement without 
delay. This time depends on the moment that osseointe-
gration occurs, being bone density the most important 
factor to take place (3-5). 
Melatonin (N - acetyl-5- methoxytryptamine) is a hor-
mone with paracrine,autocrine and endocrine antioxi-
dant actions (6,7).
This molecule is synthesized primarily in the pineal 
gland to 30 years of age, time at which production de-
creases. It is also synthesized in other regions such as 
retina, gastrointestinal tract, skin, bone marrow and 
lymphocytes (8). One of its main physical and chemical 
characteristics is its high diffusion capacity since it is a 
highly lipophilic molecule. It also has a very high redox 
potential, which determines an antioxidant activity far 
higher than other known antioxidants (7,8). It has been 
demonstrated the efficacy of melatonin in the treatment 
of diseases caused by the presence of free radicals (7). 
It produces intense antiapoptotic signals even in situa-
tions of ischemia and has cytoprotective properties of 
enzymes involved in the healing process. It also stimu-
lates the immune system and has oncosupresor proper-
ties (7). 
The main mechanism of melatonin on surgical wound-
seems to be inhibition of the production of reactive oxi-
dants, such as nitric oxide (NO) and nitrotyrosine (NT)
(9), by reducing the activation of NF- kβ (10), expres-
sion of COX-2 and prostaglandin, and recruitment of 
polymorphonuclear cells into the site of injury (6,11,12). 
Moreover,melatonin reduces neutrophil infiltration and 
neutralizes the exacerbated production of inflammatory 
mediators such as necrosis tissue factor-α (NTF-α) and 
several interleukins (IL- 1β and IL -6) (6,13-16). It is 
known that the maximum antinociceptive effect of me-
latonin was observed 60 minutes after the systemically 
administration of high doses (17,12). 
Regarding the bone, several studieshave reported that 
melatonin plays an important role in bone formation 
and bone metabolism (18,19). It has been shown that lo-
cally applied melatonin increases trabecular bone for-
mation directly by stimulating osteoblasts early from 
endosteum (19,20), and accelerating the synthesis and 
mineralization of the osteoid matrix after 2 and 4 weeks 
(10,21). This resultsin a significant increase in cortical 
width and length of bone (20,21). It also increases bone 
formation markers, such as alkaline phosphatase, sialo-
protein, osteopontin, and osteocalcin (22). Moreover, it 
interferes with osteoclast function, inhibiting bone re-
sorption directly and by reducing RANKL (21). 
Consequently, there is scientific evidence of the poten-
tial of melatonin in the treatment of inflammation and 
pain (6,10,23) and as a osteogenic factor that increases 
the volumeand bone density (20). It is also known that 
its effects are proportionally related to the dose applied, 
and there is general agreement that melatonin may be 
applied with insignificant adverse effects even at high 
doses (10,23).  
Therefore, we hypothesize that local application of me-
latoninin the post- extraction socket produces favorable 
differences in the immediate postoperative period, as 
anti-inflammatory, analgesic and early osteogenic re-
garding the natural healing process of the socket. 
For this set itwas aimed to determine whether there 
were differences in the levels of interleukin -6 and ni-
trotyrosine and bone density as a function of applied 
locally melatonin, assessing the possible complications 
associated with postoperative melatonin.
Material and Methods
-Patients
Ten patients of the Department of Medicine and Oral 
Surgery, Faculty of Dentistry, Complutense University 
of Madrid indicating both lower third molar extraction, 
with good health (Category I and II of the American 
Society of Anesthesiologists [ASA]) of both sexes, aged 
between 16 and 35, were included. Subjects would not 
have a history or metabolic or systemic diseases affect-
ing bone or healing process, no locally periodontal dis-
ease or cystyc or tumorpathology. In addition, due to 
standardize the sample, both third molarwere in simi-
larposition and situation. Subjects who met the inclu-
sion criteria and agree to sign the informed consent 
were included in the study.
Were considered as an exclusion criteria smoking, preg-
nant or breast-feeding, use of contraceptives or hormo-
nal medications, the presence of chronic disorders, and 
history of allergy or adverse effects associated with the 
drugs used as well as the presence of acute inflamma-
tion or infection the day of surgery. The operation time 
was timed from the beginning of the incision to the 
end of suture, and if it exceeded 30 minutes, the patient 
would be excluded. Also would be excluded those who 
do not allow monitoring and sampling.
Both extractions were performed in the same sequence 
by the same operator. Melatonin (3 mg melatonin into 
2 ml hydroxyethylcellulose gel 2%) in the socket is ap-
plied randomly by computer versus placebo (2 ml ofhy-
droxyethylcellulose gel 2 %). In all cases the same an-
tibiotic, antiinflammatory, analgesic and surgical inten-
sive gastroprotective was prescribed. Healing process 
was revised and proceeded to suture removalat 7 days.
Patient information, treatment and samples were coded 
so that the side of the treatment was unknown to the 
patient, the surgeon and for the data analysis.
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Besides the occurrence of adverse events were recorded 
over a time period of two months after the extraction.
-Bone density measurement
A digital cone beam scanner before surgery was car-
ried out (Model 17-19 Next Generation i-CAT ® Imag-
ing Sciences International, Inc.Hatfield, Pennsylvania, 
USA) and another at 60 days was obtained.
Bone densities were compared (i-CAT Vision program 
Imaging Sciences International ® version 1.8) by meas-
uring Hounsfield Units by area (HU) using the method 
of quantitative subtraction radiography. In the pano-
ramic image previous to extractions measuring 10 ar-
eas of lower third molar and 10 equal areas of bone in 
the region distal was performed. Measurements were 
made on both sides, avoiding overlapping cortical and 
anatomical structures. In addition, 10 cross sections of 
each side of the region of the lower ridge, on which five 
socket areas were measured, and five areas of the distal 
bone region were selected.
-Plasma measurements
IL-6 and NT were measured by ELISA from the clot ob-
tained into the socket in order to quantify the anti-inflam-
matory effect (IL-6) and the analgesic effects (NT). 
The first blood sample was obtained by direct extraction 
from the socket immediately after the tooth extraction. 
The second blood sample was obtained similarly to 60 
minutes after completing the intervention.
-Statistical analysis
Data were analyzed using statistical package SPSS 
21.0 for Windows (SPSS Inc., Chicago, IL, USA). Kol-
mogorov-Smirnov test was applied to determine the 
distribution of serum analysis data. Shapiro-Wilk test 
for bone density analysis was used. After proving to be 
accepted normality of samples t test was applied. The 
significance level was set as P<0.05.
Results
Ten patients (9 females: 1 male) were studied, with a 
mean age of 22.60 ± 2.17 years. Samples were coded 
as: “a” side of melatonin prior, “b” side of control prior, 
“A” side melatonin later, “B” side control later. Time of 
surgery in any case exceed 30 minutes.
5B and 10B samples could not be analyzed by ELISA 
due to get as non-processable after centrifugation.
The concentrations of IL -6 before application of mela-
tonin (11.17 ± 11.03 pg/ml) and placebo (15.03 ± 21.92 
pg/ml)were not significantly different. After the appli-
cation, there were no significant differences between 
melatonin (361.32 ± 235.22 pg/ml) and placebo (262.58 
± 233.92 pg/ml) in terms of the concentration of IL -6 
(Fig. 1) .
Statistical analysis of the concentrations of NT could 
not be performed because the optical density values ob-
tained in most of the samples were below the detectabi-
lity standard curve. The lower limit of detection is set 
at concentrations <0.001 nM, so the NT of the samples 
were insignificant.
In the study of bone density at 60 days, one patient had 
to be excluded from the sample. Despite being excluded 
from the sample by radiographic study, monitoring was 
performed and adverse events are described.
In the panoramic sections no significant differences in 
bone distal region previously (a = 609.39 ± 173.28 HU; b 
= 620.59 ± 177.36 HU) and after extraction were found 
(A = 631.40 ± 91.08 HU; and B = 684.66 ± 115.50 HU). 
No differences in the sockets were seen between the ap-
plication of melatonin (561.98 ± 105.92 HU) and placebo 
(598.82 ± 209.03 HU) at two months (Table 1).
In the cross sections no differences in bone distal re-
gion were found before (a = 358.36 ± 143.29 HU; b = 
322.44 ± 124.62 HU), and aftertreatment application (A 
= 466.56± 213.74 HU;B = 434.47 ± 188.87 HU). Bone 
density in the alveolar region after application of mela-
tonin (A = 377.42 ± 125.67 HU) and placebo (B = 347.56 
± 97.02 HU) showed no significant differences. 
Discussion
This is the first work where the anti-inflammatory, anal-
gesic and osteogeniceffects of melatonin are measured 
after extraction of third molar in patients.
An increase in inflammation and pain have been described 
in surgical procedures of longer duration, so the time of 
surgery has been considered an indicator of difficulty (1,2). 
The present study is within the time of surgery recorded by 
other authors, between 11.03 and 25.00 minutes (2).
Fig. 1. Concentrations of IL-6 (pg/ml).”a” side melatonin prior, “b” 
side control prior, “A” side melatoninlater, “B” side controllater. The 
concentration of IL-6 before treatment (11.17 ± 11.03 vs 15.03 ± 21.92 
pg/ml) no significant differences (P = 0.517). The concentration after 
application of melatonin versus control (361.32 ± 235.22 vs 262.58 
± 233.92 pg/ml) no statistically significant difference (P = 0.465). 
There are significant differences in the concentration of IL-6 in ad-
vance and then to treatment with melatonin (P = 0.001), and with 
placebo (P = 0.026).
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Despite obtaining a sufficient amount of blood for 
processing all samples, there were two post- placebo 
gel application whose plasma samples could not be ana-
lyzed as having an oily consistency. This may be due 
to the limited local bleeding, which mixed with the gel, 
resulted in animpossible processing of the sample.
Regarding the concentration of IL-6, on both sides there 
was a non-inflammatory state before treatment applica-
tion. After treatment no significant differences in the 
concentration of IL-6 were found, so our study can-
not claim that melatonin influences the concentration 
of IL-6 in relation to the early inflammatory process. 
A possible explanation, according to Mayo et al. (24), 
Cutando et al. (9) and Radogna et al. (6), should be that 
the greatest effect of melatonin occurs when inflam-
matory mediators are increased in the damaged region. 
Another factor related to its effect, according to Maldo-
nado et al. (16) and Laste et al. (12), is the dose applied, 
which could be small in our study, although antiinflam-
matory and analgesic effects are described applying lo-
cally 2 mg (9)and even micromolar doses (6,23). 
The NO has a rapid degradation of compounds such as 
nitrotyrosine, so determination can detect earliest and 
smaller changes (17,25). In most samples, values below 
to detectable (<0.001 nM) were obtained. Although it 
is not possible to draw conclusions from these findings 
it follows that the values of products of oxidative and 
nitrosative degradation immediately after extractions 
are not yet high enough to be quantified, according to 
Hamza et al. (17)in extraction of wisdom teeth, which 
were not detectable. Furthermore, studies such as Mayo 
et al. (24) support the utility of melatonin as anti-in-
flammatory agent but its effects would be amplified 
when free radicals and inflammatory mediators were 
already present in the injured area (17). 
In the study of bone density, a patient had to be exclud-
ed from the sample due to an allergic reaction. He also 
received surgical treatment in the region operated due 
to a postoperative complication and was not possible to 
makethe mandibular scanner on deadline. The exclu-
sion of this patient supposed that all the patients in the 
sample were women.
Bone density was obtained in panoramic sections in the 
distal regions (a = 609.39 ± 173.28 HU; b = 620.59 ± 
177.36HU; A = 631.40 ± 91.08 HU; B = 684.66 ± 115.50 
HU). This was comparable to that obtained by Hiasa et 
al. (26), Norton et al. (27), and Turkyilmaz et al. (28) in 
the same region (628.2±209.2HU (26), 669HU (27) and 
715.8±190HU (28)), considering that bone density use to 
be lower in women and younger patients (29). No signi-
ficant differences in bone density in the alveolar region 
were observed according to the treatment (a = 561.98 ± 
105.92 HU;B = 598.82 ± 209.03 UH), although values 
are closeto the control region.
In the cross sections bone density in the alveolar regions 
(A = 377.42 ± 125.67 HU; B = 347.56 ± 97.02 HU) does 
not depend on the treatment and they were much lower 
than those obtained in sections of the same region in 
the study of González- García et al. (30), (524.3 ± 169.5 
HU) in older patients.
Complications were recorded and the usual therapeu-
tic approach in each case was adopted to achieve its 
resolution effectively. From the third day, two patients 
reported dizziness, which were progressively reduced 
until it disappears in a maximum of four days of occur-
rence. A lower lipdysesthesia happened on the side of 
Alveolar region in panoramic section Distal bone region in panoramic section
a A b B a A b B
Mean 1135,200 561,978 1244,011 598,822 609,389 631,400 620,589 684,659
Stand. Desv 169,781 105,920 113,260 209,034 173,277 91,077 177,359 115,497
Alveolar region in cross section Distal bone region in cross section
a A b B a A b B
Mean 1634,378 377,422 1673,178 347,556 358,356 466,556 322,444 434,467
Stand. Desv 273,239 125,673 180,229 97,015 143,290 213,742 124,620 188,870
Table 1. Descriptive values of bone density (UH). “UH “ Hounsfield Units, “a” side melatonin prior, “b “ side control prior, “A” side melatoni 
later, “B “ side controllater”. Bone density in the alveolar region prior to treatment adopts very high tailpiece being present in both the courts 
and the scenic cross sections values. After application of melatonin has lower bone density but without statistically significant differences from 
the control (P = 0.593) in panoramic sections, and (P = 0.223) in the cross sections values. Bone of the distal region, no statistically significant 
difference in bone density previously and subsequently to the treatment with melatonin (P = 0.669) on panoramic sections, and (P = 0.080) in 
the cross sections. The distal bone region no significant differences after application of melatonin or placebo in panoramic sections (P = 0.191) 
and in the cross sections (P = 0.391).
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melatoninand was resolved within 3 days with anti-in-
flammatory therapy. One patient reported fever of 39°C, 
discarding oral origin at examination. Another patient 
had a post-extraction alveolitis on the side of melatoni-
napplication. At 36 days she developed an increasingly 
severe noninfectious inflammation due to trauma in the 
periosteum, which was resolved 10 days after. Finally, 
one patient showed an allergic reaction to metamizol 
575 mg, not mentioned in the medical record at 10 hours 
after surgery. At 35 days, he went to the emergencies 
with an increased inflammation, trismus and night pain 
on the side where melatonin was applied. He was di-
agnosed of “paramandibular abscess of 38” and treated 
with surgical drainage and antibiotic (ciprofloxacin 500 
mg), anti-inflammatory (ibuprofen 600 mg), analgesic 
(paracetamol 650 mg) and an antiseptic (chlorhexidine 
0.2%) therapy.
Despite the reported complications, the distribution of 
the samedoes not determine its relation to the applica-
tion of melatonin.
Conclusion
Finally, within the limitations of this study, we can 
conclude that there were no differences between the ap-
plication of melatonin and placebo in terms of the con-
centration of interleukin-6 and bone density. No differ-
ences could be determined between nitrotyrosine levels 
before and after the treatment. Thus, we must conclude 
that the treatment is not influential. Moreover, it was not 
possible to establish a causal relationship of melatonin 
with complications occurring during the postoperative 
period. Further researches are necessary by applying 
higher doses of melatonin and extending the sample 
with an appropriate methodology in order to confirm 
these results.
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